{"id":17237,"date":"2021-10-04T11:17:41","date_gmt":"2021-10-04T10:17:41","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=17237"},"modified":"2023-06-06T15:22:39","modified_gmt":"2023-06-06T14:22:39","slug":"who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/","title":{"rendered":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline"},"content":{"rendered":"\n<p>Article published on September 29, 2021, on the <a href=\"https:\/\/www.who.int\/news-room\/articles-detail\/who-2021-data-call-entry-for-antibacterials-in-the-preclinical-development-pipeline\" target=\"_blank\" rel=\"noreferrer noopener\">World Health Organization website<\/a><\/p>\n\n\n\n<p>Opening date: 30 September 2021 at 12:00 Geneva time<\/p>\n\n\n\n<p>Closing date: 30 October 2021 at 23:30 Geneva time<\/p>\n\n\n\n<p><strong>Introduction<\/strong>&nbsp;<\/p>\n\n\n\n<p>In January 2019 and 2020, the World Health Organization (WHO) released its first performed&nbsp;<a href=\"https:\/\/doi.org\/10.1371\/journal.pone.0236604\" target=\"_blank\" rel=\"noreferrer noopener\">global reviews of the preclinical antibacterial pipeline<\/a>, based on publicly available data primarily gathered through a WHO data call.<\/p>\n\n\n\n<p>A&nbsp;2020&nbsp;update of the antibacterial&nbsp;preclinical data&nbsp;analyses report&nbsp;was performed and&nbsp;is available on the open source&nbsp;<a target=\"_blank\" href=\"https:\/\/www.who.int\/data\/gho\/data\/themes\/antimicrobial-resistance-(amr)\" rel=\"noreferrer noopener\">WHO Global Health R&amp;D Observatory<\/a>, and&nbsp;was&nbsp;published in the\u202fWHO Report&nbsp;<a target=\"_blank\" href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240021303\" rel=\"noreferrer noopener\">2020 antibacterial agents in clinical and preclinical development: an overview and analysis<\/a>.&nbsp;<\/p>\n\n\n\n<p><strong>WHO&nbsp;2021&nbsp;data call for&nbsp;antibacterial, and antifungal agents in preclinical development pipeline<\/strong><\/p>\n\n\n\n<p>WHO 2021 data call aims to collect data on:<\/p>\n\n\n\n<ol><li>The 2021 update of WHO analysis and review antibacterial agents in the preclinical development pipeline.\u202f<\/li><li>The first WHO analysis of antifungal agents in the preclinical development pipeline.<\/li><\/ol>\n\n\n\n<p>The 2021&nbsp;preclinical data analyses&nbsp;will feed into the WHO Global Health R&amp;D Observatory. The analyses and&nbsp;data&nbsp;will be available for&nbsp;all&nbsp;stakeholders including existing and future funders of R&amp;D.&nbsp;<\/p>\n\n\n\n<p>We would like to thank those who have responded&nbsp;to previous&nbsp;WHO data calls&nbsp;and&nbsp;encourage their and others continued participation, without which this review would not be possible.&nbsp;<\/p>\n\n\n\n<p><strong>Scope and definitions<\/strong><\/p>\n\n\n\n<p>For this data call\/review, the term \u201cpreclinical products\u201d refers to all products<strong><sup>*<\/sup><\/strong>\u202ffrom lead-optimization (post hit expansion), preclinical candidate, to formal CTA\/IND enabling studies prior to the commencement of human testing. &nbsp;<br>&nbsp;<\/p>\n\n\n\n<ul><li><strong>Lead optimization:<\/strong>\u202fiterative in vitro and in vivo screens of lead compounds to generate suitable pharmacological, safety and pharmacokinetic profiles of one or more candidates to progress into preclinical development. &nbsp;<\/li><li><strong>Preclinical candidate:<\/strong>\u202fa lead compound, or a shortlist of compounds that are being actively compared, that have been evaluated in initial toxicology tests and demonstrates the required safety profile which when combined with a suitable understanding of pharmacological efficacy warrants advancement.<\/li><li><strong>CTA\/IND-enabling studies:<\/strong>\u202fstudies including detailed ADME (absorption, distribution, metabolism and excretion) studies and GLP (good laboratory practice) toxicology, as well as formulation and manufacturing development necessary to obtain the permission of regulatory authorities to begin human clinical testing.&nbsp;<\/li><\/ul>\n\n\n\n<p><br><sub><strong><sup>*<\/sup><\/strong><\/sub><strong><sub>Note:<\/sub><\/strong><sub><em>For any given program, if a medicinal chemistry backup program is ongoing in parallel with the advancement of a lead compound(s) in the same chemical&nbsp;series then the development phase of the most advanced compound being actively studied should be recorded.<\/em>&nbsp;<\/sub><\/p>\n\n\n\n<p><strong>Inclusion&nbsp;criteria and&nbsp;scope of&nbsp;WHO&nbsp;analysis\u202ffor&nbsp;antibacterial&nbsp;agents&nbsp;in preclinical development<\/strong><\/p>\n\n\n\n<p>Products that are active against WHO bacterial priority pathogens,&nbsp;<em>M. tuberculosis<\/em>, or&nbsp;<em>C. difficile&nbsp;<\/em>should be included in the preclinical pipeline analysis.\u202f\u202fThese include:&nbsp;<\/p>\n\n\n\n<ol><li>Directly and indirectly acting small molecule antibacterial agents (including antimycobacterial drugs)<\/li><li>Anti-virulence agents and biofilm disruptors\u202f<\/li><li>Potentiators or enablers that improve activity of existing products (e.g., resistance modulating agents, BLI, penetration enablers, efflux inhibitors)<\/li><li>Large molecules (natural products, e.g., antimicrobial peptides or biologics like for example antibodies, bacteriophages and bacteriophages derived products)<\/li><li>Microbiome modifying agents<\/li><li>Immunomodulators<\/li><li>Repurposed non-antibiotics<\/li><li>Repurposed from animal to human use antibiotics<\/li><li>De-colonization agents<\/li><li>Combination therapies<\/li><\/ol>\n\n\n\n<p><strong>Exclusion criteria (for antibacterial agents in preclinical development)<\/strong><\/p>\n\n\n\n<p>Products excluded from this analysis are diagnostics, antivirals and antiparasitics as they are covered through other WHO&nbsp;programmes. Antifungals are also excluded form and are covered by a separate data collection form (Please see at the end of this page the form links).&nbsp;<\/p>\n\n\n\n<p>In addition, wound care products, unspecific supportive treatments,&nbsp;topical or locally administered products targeting mild skin or local infections, products targeting bacteria beyond the scope of the&nbsp;WHO priority pathogens list,\u202f<em>M. tuberculosis and C. difficile<\/em>, medical devices, industrial or animal use are also not included.&nbsp;<\/p>\n\n\n\n<p><strong>Inclusion criteria and scope of WHO analysis<\/strong>\u202f<strong>for antifungal agents in preclinical development<\/strong>&nbsp;<\/p>\n\n\n\n<p>Products that are&nbsp;administered systemically or locally and are&nbsp;active against&nbsp;invasive infections due to&nbsp;selected&nbsp;fungal&nbsp;pathogens&nbsp;(pathogens and indications are&nbsp;included&nbsp;in the&nbsp;survey form),&nbsp;including:<\/p>\n\n\n\n<ol><li>Small molecule &#8211; direct acting&nbsp;<\/li><li>Small molecule &#8211; indirect acting&nbsp;<\/li><li>Peptide &#8211; direct acting&nbsp;<\/li><li>Peptide &#8211; indirect acting&nbsp;<\/li><li>Large molecule &#8211; direct acting&nbsp;<\/li><li>Large molecule &#8211; indirect acting&nbsp;<\/li><li>Antibody-drug conjugate (ADC)&nbsp;<\/li><li>Biologic (Antibody or other biotherapeutics)&nbsp;<\/li><li>Immunomodulators&nbsp;<\/li><li>Others<\/li><\/ol>\n\n\n\n<p><strong>Exclusion criteria (for antifungals<\/strong><strong>&nbsp;agents in preclinical development): &nbsp;<\/strong><\/p>\n\n\n\n<p>Products excluded from this analysis are diagnostics, antivirals and&nbsp;antiparasitic agents&nbsp;as they are covered through other WHO&nbsp;programs.&nbsp;&nbsp;Antibacterial&nbsp;agents&nbsp;in preclinical development&nbsp;are excluded as&nbsp;they&#8217;re&nbsp;covered by a separate&nbsp;data collection&nbsp;form (please see at the end of this page the form links).&nbsp;<\/p>\n\n\n\n<p>In&nbsp;addition, excluded are&nbsp;wound care products, unspecific supportive treatments,&nbsp;products targeting&nbsp;fungi&nbsp;beyond the scope of&nbsp;the review (as outlined in the data collection form),&nbsp;topical&nbsp;or locally administered&nbsp;products targeting mild skin&nbsp;or local&nbsp;infections,&nbsp;medical devices, industrial or animal use are also not included.&nbsp;<\/p>\n\n\n\n<p>Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the above inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&amp;D Observatory.&nbsp;<\/p>\n\n\n\n<p><strong>Data collection form links:<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/extranet.who.int\/dataformv3\/index.php\/725634?lang=en\" target=\"_blank\" rel=\"noreferrer noopener\">WHO 2021 survey on antibacterial agents in the preclinical development pipeline<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/extranet.who.int\/dataformv3\/index.php\/575487?lang=en\" target=\"_blank\" rel=\"noreferrer noopener\">WHO 2021 survey on antifungal agents in the preclinical development pipeline<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on September 29, 2021, on the World Health Organization website Opening date: 30 September 2021 at 12:00 Geneva time Closing date: 30 October 2021 at 23:30 Geneva time Introduction&nbsp; In January 2019 and 2020, the World Health Organization (WHO) released its first performed&nbsp;global reviews of the preclinical antibacterial pipeline, based on publicly available [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":17243,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-04T10:17:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T14:22:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"638\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline\",\"datePublished\":\"2021-10-04T10:17:41+00:00\",\"dateModified\":\"2023-06-06T14:22:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\"},\"wordCount\":964,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\",\"name\":\"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg\",\"datePublished\":\"2021-10-04T10:17:41+00:00\",\"dateModified\":\"2023-06-06T14:22:39+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg\",\"width\":638,\"height\":425,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/","og_locale":"en_GB","og_type":"article","og_title":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-10-04T10:17:41+00:00","article_modified_time":"2023-06-06T14:22:39+00:00","og_image":[{"width":638,"height":425,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline","datePublished":"2021-10-04T10:17:41+00:00","dateModified":"2023-06-06T14:22:39+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/"},"wordCount":964,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/","name":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg","datePublished":"2021-10-04T10:17:41+00:00","dateModified":"2023-06-06T14:22:39+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/10\/JeunePousse.jpg","width":638,"height":425,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/who-2021-data-call-is-now-open-for-both-antibacterials-and-antifungals-in-the-preclinical-development-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"WHO 2021 data call is now open for both antibacterials and antifungals in the preclinical development pipeline"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-15 23:03:08","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/17237"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=17237"}],"version-history":[{"count":14,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/17237\/revisions"}],"predecessor-version":[{"id":17541,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/17237\/revisions\/17541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/17243"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=17237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=17237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=17237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}